Key result
Intravenous dexamethasone significantly reduced Interleukin-6 and increased Interleukin-10 levels (p<0.001) but did not improve short-term clinical parameters compared to placebo.
Why the study?
Does intravenous dexamethasone reduce inflammatory markers and improve clinical parameters in children undergoing open-heart surgery for congenital heart disease?
RCT (n=152)
Does intravenous dexamethasone reduce inflammatory markers and improve clinical parameters in children undergoing open-heart surgery for congenital heart disease?
Intravenous dexamethasone modulates the inflammatory response after cardiopulmonary bypass in children but does not yield short-term clinical benefits.
Does not support routine dexamethasone use for clinical benefit in pediatric congenital heart surgery; confirms cytokine modulation without short-term outcome gains.
BACKGROUND: Cardiopulmonary bypass is associated with systemic inflammatory response. Steroids suppress this response, although the therapeutic evidence remains controversial. We hypothesised that intravenous steroids in children undergoing open-heart surgery would decrease inflammation leading to better early post-operative outcomes. We conducted a randomised controlled trial to evaluate the trends in the levels of immunomodulators and their effects on clinical parameters. OBJECTIVE: To assess the effects of intravenous steroids on early post-operative inflammatory markers and clinical parameters in children undergoing open-heart surgery. MATERIALS AND METHODS: A randomised controlled trial involving 152 patients, from one month up to 18 years of age, who underwent open-heart surgery for congenital heart disease from April 2010-2012 was carried out. Patients were randomised and administered either three scheduled intravenous pulse doses of dexamethasone (1 mg/kg) or placebo. Blood samples were drawn at four time intervals and serum levels of inflammatory cytokines - Interleukin-6, 8, 10, 18, and tumour necrosis factor-alpha - were measured. Clinical parameters were also assessed. RESULTS: Blood cytokine levels were compared between the dexamethasone (n=65) and placebo (n=64) groups. Interleukin-6 levels were lower at 6 and 24 hours post-operatively (p<0.001), and Interleukin-10 levels were higher 6 hours post-operatively (p<0.001) in the steroid group. Interleukin-8, 18, and tumour necrosis factor-alpha levels did not differ between the groups at any time intervals. The clinical parameters were similar in both the groups. CONCLUSION: Dexamethasone caused quantitative suppression of Interleukin-6 and increased Interleukin-10 activation, contributing to reduced immunopathology, but it did not translate into clinical benefit in the short term.
No takes yet. Share an insight, caveat, or question.
Amanullah et al. (2015) conducted an RCT in congenital heart disease requiring open-heart surgery (n=152). dexamethasone vs. placebo was evaluated on serum levels of inflammatory cytokines (IL-6, IL-8, IL-10, IL-18, TNF-alpha) and clinical parameters (p=<0.001). Intravenous dexamethasone significantly reduced Interleukin-6 and increased Interleukin-10 levels (p<0.001) but did not improve short-term clinical parameters compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: